Daily antibiotic use could reduce COPD flare-ups, study finds

Share this article:

Long-term daily doses of the antibiotic azithromycin helped prevent life-threatening flare-ups of chronic obstructive pulmonary disease, a new study finds.

COPD, a chronic lung disease that includes emphysema and chronic bronchitis, can be worsened by bacterial and viral infections that can cause flare-ups of the disease, leading to frequent hospital and doctor's office visits. In a recent study of 1,100 people with COPD, ages 40 and up, one group received a placebo pill while the other was given azithromycin. After one year, participants taking the antibiotic daily were 27% less likely to experience a flare-up in their COPD symptoms than the group taking the dummy pill.

The antibiotic has been linked to irregular heartbeats in some people, and has been associated with hearing loss in people with hearing impairments, so researchers stress that physicians should use caution when prescribing azithromycin. According to the study, investigators suspect the drug might have anti-inflammatory properties that calm COPD.

"If, after trying all of the standard treatments, patients are still having acute exacerbations of COPD, adding azithromycin to the treatment regimen will decrease the number of exacerbations," Richard Albert, M.D., told HealthDay News.

The study was published in Thursday's issue of the New England Journal of Medicine.
Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.